Fundraising Fox
/Companies
Sign in

Indaptus Therapeutics

NASDAQ: INDP

New York, US · Founded 2021 · Delaware corporation

Find your way into Indaptus Therapeutics

Sign up to see every warm intro you have to Indaptus Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Indaptus Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Indaptus Therapeutics is a development-stage biopharmaceutical company conducting preclinical and clinical research on product candidates; the company has no approved products and generates no revenue from product sales, and funds operations through equity and debt financing.

Biotech

Founders & leadership

RW
ROGER WALTZMANExecutive
NSNir Sassi
Nir SassiExecutive
JAJeffrey A. Meckler
Jeffrey A. MecklerChief Executive Officer
MJ
Michael J. NewmanChief Scientific Officer
WAWalt A. Linscott
Walt A. LinscottChief Operating Officer
HL
HOONMO LEENamed on SEC filing
BO
BRIAN O'CALLAGHANNamed on SEC filing

Board

AM
ANTHONY MADDALUNABoard director
WB
WILLIAM B. HAYESBoard director
RE
ROBERT E. MARTELLBoard director
RJ
ROGER J. POMERANTZBoard director
HK
HILA KARAHBoard director

Reported raises · per SEC filings

Form D private placements

$35M disclosed across 5 rounds · 2021–2025

▶$2.3MraisedJun 2025 · 20 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Anthony MaddalunaDirector
  • Hila KarahDirector
  • Robert E. MartellDirector
  • Walt A. LinscottExecutive Officer
  • Roger PomerantzDirector
  • William B. HayesDirector
  • Mark J. GilbertDirector
  • Roger J. WaltzmanExecutive Officer
  • Michael J NewmanExecutive Officer, Director
  • Jeffrey A. MecklerExecutive Officer, Director
  • Nir SassiExecutive Officer
Offering amount
$5M
Amount sold
$2.3M
Sales commissions
$600K
Placement agents
Paulson Investment Company, LLC
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2.2MraisedJan 2025 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ROGER J. POMERANTZDirector
  • ANTHONY MADDALUNADirector
  • ROGER WALTZMANExecutive Officer
  • MARK J GILBERTDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • JEFFREY A. MECKLERExecutive Officer, Director
  • NIR SASSIExecutive Officer
  • WALT A LINSCOTTExecutive Officer
  • WILLIAM B. HAYESDirector
  • HILA KARAHDirector
  • ROBERT E. MARTELLDirector
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$157.3K
Placement agents
Paulson Investment Company, LLC
First sale
Jan 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$227.1KraisedDec 2024 · 20 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • MARK J GILBERTDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • NIR SASSIExecutive Officer
  • WILLIAM B. HAYESDirector
  • ROGER WALTZMANExecutive Officer
  • WALT A LINSCOTTExecutive Officer
  • ANTHONY MADDALUNADirector
  • JEFFREY A. MECKLERExecutive Officer, Director
  • HILA KARAHDirector
  • ROGER J. POMERANTZDirector
  • ROBERT E. MARTELLDirector
Offering amount
$227.1K
Amount sold
$227.1K
Sales commissions
$15.5K
Placement agents
Paulson Investment Company, LLC
First sale
Nov 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$205.5KraisedOct 2024 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ANTHONY MADDALUNADirector
  • WILLIAM B. HAYESDirector
  • MICHAEL J. NEWMANExecutive Officer, Director
  • ROBERT E. MARTELLDirector
  • ROGER WALTZMANExecutive Officer
  • JEFFREY A. MECKLERExecutive Officer, Director
  • ROGER J. POMERANTZDirector
  • HILA KARAHDirector
  • NIR SASSIExecutive Officer
  • MARK J GILBERTDirector
  • WALT A LINSCOTTExecutive Officer
Offering amount
$205.5K
Amount sold
$205.5K
Sales commissions
$17.5K
Placement agents
Paulson Investment Company, LLC
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • HOONMO LEEDirector
  • MICHAEL NEWMANExecutive Officer, Director
  • ANTHONY J. MADDALUNADirector
  • ROGER J. POMERANTZDirector
  • HILA W. KARAHDirector
  • JEFFREY A. MECKLERExecutive Officer, Director
  • WILLIAM B. HAYESDirector
  • BRIAN O'CALLAGHANDirector
  • NIR SASSIExecutive Officer
  • WALT A LINSCOTTExecutive Officer
Offering amount
$30M
Amount sold
$30M
Sales commissions
$2.1M
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Indaptus Therapeutics (INDP) sells 20M shares in $12M Regulation S private placementstocktitan.net · Jun 2026Indaptus posts Q1 2026 loss, cash down to $1.5M | INDP 8-K Filingstocktitan.net · May 2026

Frequently asked questions

What does Indaptus Therapeutics do?
Indaptus Therapeutics is a development-stage biopharmaceutical company conducting preclinical and clinical research on product candidates; the company has no approved products and generates no revenue from product sales, and funds operations through equity and debt financing.
How much funding has Indaptus Therapeutics raised?
Indaptus Therapeutics has disclosed $35M raised across 5 rounds.
Where is Indaptus Therapeutics headquartered?
Indaptus Therapeutics is headquartered in New York, US.